about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesMolecular Testing in Patients with Suspected Myelodysplastic Syndromes.Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs.HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells.Human and rhesus macaque hematopoietic stem cells cannot be purified based only on SLAM family markers.Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.Chronic myeloid leukemia: changing the treatment paradigms.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 TherapyGetting to the stem of chronic myeloid leukaemia.Erythropoietin-stimulating agents in oncology.High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.Overcoming resistance in chronic myelogenous leukemia.Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia.Are we altering the natural history of primary myelofibrosis?Unfavorable-risk acute myeloid leukemia dissected.Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes.A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.The failure of years of experience with electrocardiographic transmission from paramedics to the hospital emergency department to reduce the delay from door to primary coronary intervention below the 90-minute threshold during acute myocardial infarGuadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.Comparison of a semipermeable dressing bonded to an absorbent pad and a semipermeable dressing over a separate gauze pad for containment of vaccinia virus at the vaccination site.Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia.Detection of vaccinia DNA in the blood following smallpox vaccination.Therapy for Chronic Myelomonocytic Leukemia in a New Era.Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML.Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia.Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in Combination With Standard Chemotherapy in Patients With AML or High-Risk MDS.Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia.Low Clinical Trial Accrual of Patients With Myelodysplastic Syndromes: Causes and Potential SolutionsSynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth
P50
Q26752940-4FFFA891-61F3-4888-BCC1-02B4951A6D19Q33435980-637DE219-1761-4B5C-AA7E-F64E917564FEQ33436345-DE34676C-8ACA-4D53-B2D0-9C23AEAF25B7Q33441578-BFF56F3E-FAF0-4173-9703-FF88DDD34273Q33941997-337BF843-98C1-4010-B616-9684CECE2C94Q35007831-DA99ADE6-4D14-4D28-A7F0-13AFA636484DQ35868339-6659E62A-F255-496C-B74A-EF40EBB33805Q36107268-B4901FF9-A85B-4819-938D-43D49379844AQ36536017-DADC512A-C279-4ADB-92F7-FCC330286C60Q36708989-0B84E763-6392-40E1-9F19-9162CFBC598BQ36963592-84CB3225-CFD5-449A-B03F-F4E2CC48BB94Q37127231-49E9C749-B523-4870-AB64-3A4522FBEBDFQ37129516-CBD9F6D2-4001-4866-AB70-47BA98BBC3E3Q37200775-A3EDEE0F-A2E5-4DCB-BD5C-F58BE5009E6AQ37406149-89A53495-0A79-4161-8E68-9D83D18CA7D8Q37626054-754829A4-8CFD-4078-9747-45A3A52A4FB8Q38129296-F33A7D5C-B9EB-4220-A6BB-1E9929E24224Q38220443-EEA0F9AA-0DF6-48A2-ABC8-F4BCADA46098Q38716325-1B377335-8EBB-4653-BBDB-A673FA2EC5E7Q38815314-5B7116F7-342A-4392-A5B0-63F8AA82F0CAQ38881093-D592503A-49DB-4312-BAE0-F44F5E2A36CEQ39048645-B4CC2DFF-AE87-40C7-BDB7-44FAC56637DBQ39750381-98B70EFE-6026-4BA7-BFF2-399733725D6EQ42686182-A1673B75-C890-4877-854C-019283DE1BFCQ45399565-4EE887A3-E031-4ECC-A743-F9C521343C31Q47332491-C7474426-5962-49C9-ADA1-DFD3FB50DE0EQ47603084-AA759F08-120C-4F01-B6E1-AA5C77EA522CQ47853133-05F3FF5B-AC8A-4A10-9F9A-5D59FFDD98A1Q48216923-DB2C8A13-4FE9-4A6D-9AEB-EF104630DE28Q48518271-3D57DC4A-2824-4B48-991D-974962A7EB5AQ49599174-EB7635F4-3692-4C15-9850-802FCD579B96Q49791912-6ADE6583-CFDB-4A17-AB83-D37C89255843Q50137311-489FB5DC-E6D6-4D11-B70D-5EA2E7A47E3EQ51129616-473EBF83-7153-4E2E-ACD1-C1AA3B05B2F2Q51246643-DC5AEED6-117F-485B-ABB8-C158FE9CBC64Q51308516-2DC10925-4A3E-47E7-988E-A1429F94E1F6Q52760599-7A3207FF-0D4C-42E2-A067-16A141A7356BQ55073460-09CB902D-14D9-46A0-B112-0BFF62F81F4EQ56979015-2F742A56-A09E-4D1E-B597-1F199FF8FF74Q58543688-A4988BE2-6FCC-48C1-BF53-AE257C0AFEF9
P50
description
médico científico
@es
physician scientist
@en
wetenschapper
@nl
name
Michael Robert Savona
@en
Michael Robert Savona
@es
Michael Robert Savona
@nl
type
label
Michael Robert Savona
@en
Michael Robert Savona
@es
Michael Robert Savona
@nl
altLabel
M Savona
@en
MR Savona
@en
Michael R Savona
@en
Michael Savona
@en
prefLabel
Michael Robert Savona
@en
Michael Robert Savona
@es
Michael Robert Savona
@nl
P101
P106
P101
P21
P31
P496
0000-0003-3763-5504